PROSTAGUT-FORTE IN BENIGN PROSTATE HYPERPLASIA THERAPY: IS PATHOGENIC APPROACH?

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim of the study: to evaluate the efficiency of combined herbal drug prostagut-forte in patients with benign prostatic hyperplasia (BPH) clinically shown by lower urinary tract symptoms. Patients and methods: prostagut-forte was prescribed for 86 patients with BPH (mean age 59,3 ± 3,4 years) as monotherapy at a dose 1 capsule (280 mg) 2 times pro day for 6 month. Results show the efficiency of prostagut-forte in patients with BPH. Improvement of symptoms in 1 month was noted by 68 (79,1 %) of patients, in 3 months by 72 (83,7 %) of patients, in 6 months by 76 (88,4 %) of patients. In these periods I-PSS grade have been fallen to 31,9 %, 38,6 % and 41 % respectively. Subjective improvement was associated with improvement in indicators of the bladder outflow. In the end of the study maximal urine flow rate increased at the average for 30,8 %, the residual urine volume decreased for 48,4 %. Prostatic volume and PSA rate were not changed significantly. The most rapid effect was noted after the first month of the therapy. Conclusion: Prescription of prostagut-forte as monotherapy helps to decrease the clinical symptoms of BPH

Full Text

Restricted Access

About the authors

Igor Valentinovich Kuzmin

St.-Petersburg State I. P. Pavlov Medical University

Email: kuzminigor@mail.ru
doctor of medical science, professor, department of urology

Salman Hasunovich Al-Shukri

St.-Petersburg State I. P. Pavlov Medical University

Email: al-shukri@mail.ru
doctor of medical science, professor, head of the department of Urology

References

  1. Гориловский Л. М. Эпидемиология, факторы риска развития и биологическое течение доброкачественной гиперплазии предстательной железы // Доброкачественная гиперплазия предстательной железы / Лопаткин Н. А., ред. М., 1999. C. 12–20.
  2. Лопаткин Н. А., Сивков А. В., Медведев А. А. и др. Комплексное лечение больных аденомой предстательной железы с использованием Простагут-форте // Урология. 2006. № 2. С. 14–19.
  3. Неймарк А. И., Давыдов А. В. Комплексное лечение больных аденомой предстательной железы с использованием Простагут форте // Русский медицинский журнал. 2008. Т. 29. С. 2010–2011.
  4. Berry S. J., Coffey D. S., Walsh P. C., Ewing L. L. The development of human benign prostatic hyperplasia with age // J Urol. 1984. Vol. 132. P. 474–479.
  5. Buck A. C. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action // J Urol. 2004. Vol. 172. P. 1792–1799.
  6. Collins M. M., Meigs J. B., Barry M. J. et al. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort // J Urol. 2002. Vol.167, N 3. P. 1363–1366.
  7. Engelmann U., Walther C., Bondarenko B. et al. Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin // Arzneimittelforschung. 2006. Vol. 56, N 3. P. 222–229.
  8. Kohnen P. W., Drach G. W. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study // J Urol. 1979. Vol. 121. P. 755–760.
  9. Kramer G., Steiner G. E., Handisurya A. et al. Increased expression of lymphocyte- derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation // Prostate. 2002. Vol. 52. P. 43–48.
  10. Kramer G., Marberger M. Could Inflammation be a key component in the progession of benign prostatic hyperplasia? // Curr Opin in Urol. 2006. Vol. 16. P. 25–29.
  11. Kramer G., Mitteregger H., Marberger M. Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease? // Europ Urol. 2007. Vol. 51. P. 1202–1216.
  12. Lee K. L., Peehl D. Molecular and cellular pathogenesis of benign prostatic hyperplasia // J Urol. 2004. Vol. 172. P. 1784–1791.
  13. Lepor H. Pathophysiology, Epidemiology, and Natural History of Benign Prostatic Hyperplasia // Rev Urol. 2004. Vol. 6(Suppl 9). P. 3–10.
  14. Lopatkin N., Sivkov A., Walther C. et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms — a placebo-controlled, double-blind, multicenter trial // World J Urol. 2005. Vol. 23, N 2. P. 139–146.
  15. Lopatkin N., Sivkov A., Schläfke S. et al. Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms — long-term follow-up of a placebo-controlled, double-blind, multicenter trial // Int Urol Nephrol. 2007. Vol. 39, N 4. P. 1137–1146.
  16. McConnell J. D. Prostatic growth: new insights into hormonal regulation // Br J Urol. 1995. Vol. 76(Suppl 1). P. 5–10.
  17. Nickel J. C., Roehrborn C. G., O’Leary M. P. et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial // J Urol. 2007. Vol. 177(Suppl 4). P. 34–35.
  18. Nickel J. C. Inflammation and Benign Prostatic Hyperplasia // Urol Clin North Am. 2008. Vol. 35, N 1. P. 109–115.
  19. Robert G., Salagierski M., Schalken J. A., de La Taille A. Inflammation and benign prostatic hyperplasia: cause or consequence? // Prog Urol. 2010. Vol. 20, N 6. P. 402–407.
  20. Roberts R. O., Lieber M. M., Rhodes T. et al. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men // Urol. 1998. Vol. 51. P. 578–584.
  21. Stovsky M. D., Rhee K., Hartke D. Medical therapy versus surgery and minimally invasive surgical therapies for lower urinary tract symptoms and benign prostatic hyperplasia: what makes better economic sense? // Curr Urol Rep. 2007. Vol. 8, N 4. P. 289–297.
  22. St Sauver J. L., Jacobson D. J., McGree M. E. et al. Association between prostatitis and development of benign prostatic hyperplasia // J Urol. 2007. Vol. 177(Suppl N 4). P. 497.
  23. Walsh P. C., Hutchins G. M., Ewing L. L. Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supernormal // J Clin Invest. 1983. Vol. 72. P. 1772–1777.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Kuzmin I.V., Al-Shukri S.H.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ №ФС77-65570 от 04 мая 2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies